Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 10
Journal homepage
6
Views
2
CrossRef citations to date
0
Altmetric
Anticancers, Hormonals & Metabolic Disease Therapy

Overview: Inhibitors of Bone Resorption and Implications for Therapy

Mone Zaidi St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
,
ASM Towhidul Alam St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
,
Vijai S Shankar St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
,
Kevin Fairburn St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
,
Christopher L-H Huang The Physiological Laboratory, University of Cambridge, Cambridge, CB2 3EG, UK;
,
Baljit S Moonga St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
,
Jill Panetta Lilly Research Laboratories, Indianapolis, IN, 46285, USA.
,
David R Blake St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
&
Michael Pazianas St George's Hospital Medical School, London, SW17 ORE;; The London Hospital Medical College, London, EC1 2AD;
 show all
Pages 1517-1538 | Published online: 02 Mar 2011

References to Primary Literature

  • Gotfredsen, A Nilas, L RiiS, BJ Christiansen, C Bone changes occuring spontaneously and caused by oestrogen postmenopausal women: A local or generalized phenomenon? Br. M. J. 1986 292 1098–1100.
  • Riis, BJ Christiansen, C Measurement of spinal or peripheral bone mass to estimate early postmenopausal bone loss? Am. J. M. 1988 84 646–653.
  • Christiansen, C Christiansen, MS McNair, P Hagen, C Stocklund, K-E Transbol, I Postmenopausal bone loss: Controlled 2-year study in 315 normal females. Eur. J. Clin. Invest. 1980 10 273–279.
  • Christiansen, C Christiansen, MS Transbol, I Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981 i 459–461.
  • Hammond, CB Maxson, WS Current status of estrogen therapy. Fertil. Steril. 1982 37 5–25.
  • Maschchak, CA Lobo, RA Dozono-Takono, R Eggena, P Nakamura, RM Brenner, PF Mishell, DR Comparison of pharmacodynamic properties of various estrogen formulations. Am. J. Obstet. Gynecol. 1982 144 511–518.
  • Hammond, CB Maxson, WS Estrogen replacement therapy. Clin. Obstet. Gynecol. 1986.
  • Teitelbaum, SL Kahn, TJ Mononuclear phagocytes, osteoclasts and bone resorption. Miner. Electrolyte Metab. 1980 3 2–7.
  • Stevenson, JC Abeyasekera, G Hillyard, CJ Phang, KG MacIntyre, I Campbell, S Lane, G Townsend, PT Young, O Whitehead, MI Regulation of calcium regulating hormones by exogenous sex steroids in early post menopause. Eur. J. Clin. Invest. 1983 13 481–487.
  • Selby, PL Oestrogens and bone Osteoporosis, pathogenesis and management Francis, RM Kluwer Academic Publishers 1990 81–102.
  • Eriksen, EF Colvard, DS Berg, NJ Graham, ML Mann, KG Spelsberg, TC Riggs, BL Evidence of estrogen receptors in normal human osteoblasts-like cells. Science 1988 241 84–86.
  • Lin, HY Harris, TL Flannery, NS Aruffo, A Kajiehgorn, A Kolakowski, LF Jr Lodish, HF Goldring, SR Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 1991 254 1022–1024.
  • Gray, TK Flyn, TC Gray, KM Nabell, LM 17β-estradiol acts directly on the clonal osteoblast line UMR 106. Proc. Natl. Acad. Sci. USA 1987 84 6267–6271.
  • Ernst, M Heath, JK Rodan, GA Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989 125 825–833.
  • Tabibzadeh, SS Santhanan, U May, L Sehgal, P Cytokine-induced production of IFN-β2/IL-6 by freshly explanted human endometrial stroma cells: Modulation by oestradiol-17β. J. Immunol. 1989 142 3134–3139.
  • Girasole, G Jilka, RL Passeri, G Boswell, S Boder, G Williams, DC Manolagas, SC 17β-Estradiol inhibits interleukin-6 production by bone marrow stromal derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogen. J. Clin. Invest. 1992 In press.
  • Rickard, D Russell, G Gowen, M Oestradiol inhibits the release of tumor necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporosis Int. 1992 2 94–102.
  • Pacifici, R Rifas, L McCracken, R Vered, I McMurtry, C Avioli, LV Peck, WA Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin-1 release. Proc. Natl. Acad. Sci. USA 1989 86 2398–2402.
  • Ralston, SH Russell, RGG Gowen, M Oestrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 1990 983–988.
  • Turner, RT Colvard, DS Spelsberg, TC Estrogen inhibition of periosteal bone formation in rat long bones: Down-regulation of gene expression for bone matrix proteins. Endocrinology 1990 127 1346–1351.
  • MacIntyre, I Stevenson, JC Whitehead, MI Wimalawansa, SJ Banks, LM Healy, MJL Calcitonin for prevention of postmenopausal bone loss. Lancet 1988 1 900–2.
  • Gruber, HE Ivey, JL Baylink, DJ Matthew, SM Nelp, WB Sosom, K Chestnut, CH Long term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1988 33 295–303.
  • Zaidi, M Moonga, BS Bevis, PJR Bascal, ZA Breimer, LH Calcitonin gene peptides: Biology and clinical relevance. Critical Reviews in Clinical and Laboratory Sciences 1990 28 109–174.
  • Pecile, A Calcitonin and relief of pain. Bone Miner. 1992 16 187–189.
  • Seiber, P Brugger, M Kamber, P Riniker, B Rittel, W Menschliches calcitonin. III. Die synthese von calcitonin M. Helv. Chim. Acta 1986 51 2057–2061.
  • Maier, R Riniker, B Rittel, W Analogues of human calcitonin. I. Influence of modification in amino acid positions 29 and 31 and hypocalcaemic activity in the rat. FEBS Lett. 1974 48 68–71.
  • Epand, RM Epand, RF Orlowski, RC Seyler, JK Colescott, RL Conformational flexibility and biological activity of salmon calcitonin. Biochemistry 1986 25 1964–1968.
  • Galante, L Horton, R Joplin, GF Woodhouse, NJF MacIntyre, I Comparison of human porcine and salmon synthetic calcitonins in man and in the rat. Clin. Sci. 1971 40 9–10.
  • Epand, RM Epand, RF Orlowski, RC Lanigan, E Stahl, GL A comparison of the interaction of glucagon, human parathyroid hormone -(1–34)-peptide and calcitonin with dimyristoylphosphatidyl-glycerol and with dimyristoylphosphatidylcholine. Biophys. Chem. 1985 23 39.
  • Pless, J Bauer, W Bossert, H Zehnder, K Guttmann, ST Endocrinology Proc. Third Int. Symposium 1971 William Heinemann Medical Books London 67.
  • Tanuichi, H The impact of protein chemistry on Biomedical Sciences Schechter, AN, Dean, A, Goldberg, RF Academic Press Orlando, FL 1984 67.
  • Manning, M Przybylski, A Olma, A Klis, WA Kruszynski, M Wo, NC Pelton, GH Sawyer, WH No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 1987 329 839–840.
  • Schwarrtz, KE Orlowski, RC Marcus, R des-Ser2 salmon calcitonin: A biologically potent synthetic analog. Endocrinology 1981 108 831–835.
  • Morikawa, T Muniketa, E Sakakibara, S Noda, T Otani, M Synthesis of Eel-calcitonin and [Asu1,7]-Eel-calcitonin: Contribution of the disulfide bond to the hormonal activity. Experientia 1976 32 1104–1106.
  • Zaidi, M Chambers, TJ Gaines Das, RE Morris, HR MacIntyre, I A direct effect of human calcitonin gene-related peptide on isolated osteoclasts. J. Endocrinol. 1987 115 511–518.
  • Orlowski, RC Epand, RM Stafford, AR Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure. Eur. J. Biochem. 1987 162 399–402.
  • Agus, ZS Wasserstein, S Goldfarb, S PTH, calcitonin cyclic nucleotides and the kidney. Annu. Rev. Physiol. 1981 43 583–595.
  • MacIntyre, I Parsons, JA Robinson, CJ The effect of thyrocalcitonin on blood bone calcium equilibrium in the perfused tibiae of the cat. J. Physiol. 1967 191 393–405.
  • Aliopoulious, MA Gildhaber, P Munson, PL Thyrocalcitonin inhibition of bone resorption induced by parathyroid hormone in tissue culture. Science 1965 151 330–331.
  • Freidman, J Raisz, LG Thyrocalcitonin: Inhibitor of bone resorption in tissue culture. Science 1965 150 1465–1467.
  • Milhaud, G Perault, AM Moukhtar, MS Etude du mecanisme de l'action hypocalcemiante de la thyrocalcitonine. CR Academy of Science Paris 1965 D261 813.
  • Robinson, CJ Martin, TJ Mathews, EW MacIntyre, I Mode of action of thyrocalcitonin. J. Endocrinol. 1967 39 71–79.
  • Reynolds, JJ Dingle, JT Gudmundsson, TV MacIntyre, I Bone resorption in vitro and its inhibition by calcitonin. Calcitonin, Proc. Int. Symposium on Thyrocalcitonin and C-cells 1968 Taylor, SF Heinemann London 223.
  • Holtrop, NE Raisz, LJ Simmons, HA The effects of parathyroid hormone, colchicine and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J. Cell Biol. 1974 60 346–355.
  • Kallio, DM Garant, PR Minkin, C Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J. Ultrastruct. Res. 1972 39 205–216.
  • MacIntyre, I Alevizaki, M Bevis, PJR Zaidi, M Calcitonin and peptides from the calcitonin genes. Clin. Orthop. 1987 21 45.
  • Chambers, TJ Magnus, CJ Calcitonin alters behaviour of isolated osteoclasts. J. Pathol. 1982 136 27–39.
  • Chambers, TJ McSheehy, PMJ Thomson, BM Fuller, K The effect of calcium regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from rabbit long bones. Endocrinology 1985 116 234–239.
  • Chambers, TJ Fuller, K McSheehy, PMJ Pringle, JAS The effect of calcium regulating hormones on bone resorption by isolated osteoclastoma cells. J. Pathol. 1985 145 297–305.
  • Zaidi, M Fuller, K Bevis, PJR Gaines Das, RE Chambers, TJ MacIntyre, I Calcitonin gene-related peptide inhibits osteoclastic bone resorption: A comparative study. Calcif. Tissue Int. 1987 40 149–154.
  • Zaidi, M Breimer, LH MacIntyre, I The biology of the peptides from the calcitonin genes. Q. J. Exp. Physiol. 1987 72 371–408.
  • Zaidi, M Chambers, TJ Bevis, PJR Beacham, JL Gaines Das, RE MacIntyre, I Effects of peptides from the calcitonin genes on bone and bone cells. Q. J. Exp. Physiol. 1988 73 471–485.
  • Chambers, TJ Fuller, K Darby, JA Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone. J. Cell Physiol. 1987 132 92–96.
  • Moonga, BS Moss, DW Patchell, A Zaidi, M Intracellular regulation of enzyme release from rat osteoclasts and evidence for a functional role in bone resorption. J. Physiol. 1990 429 29–45.
  • Akisaka, T Gay, CV Ultracytochemical evidence for a proton-pump adenosine triphosphatase in chick osteoclasts. Cell Tissue Res. 1986 245 507–512.
  • Anderson, RE Schraer, H Gay, CV Ultrastructural immunocytochemical localisation of carbonic anhydrase in normal and calcitonin-treated chick osteoclasts. Anat. Rec. 1982 204 9.
  • Nicholson, CG Moseley, JM Sexton, PM Mendelson, FAO Martin, TJ Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterisation. J. Clin. Invest. 1986 78 355–360.
  • Lin, HY Harris, TL Flannery, NS Aruffo, A Kajiehgorn, A Kolakowski, LF Jr Lodish, HF Goldring, SR Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 1991 254 1022–1024.
  • Juppner, H Abou-Sanra, A-B Freeman, M Kong, FX Schipani, E Richards, J Kolakowski, LF Jr Hock, J Potts, JT Jr Kronenberg, HM Segre, GV A G protein linked receptor for parathyroid hormone-related peptide. Science 1991 254 1024–1026.
  • Chakarborty, M Chatterji, D Kellokumpus, SH Baron, R Cell dependent coupling of calcitonin receptor to different G proteins. Science 1991 251 1078–1081.
  • Zaidi, M Datta, HK Moonga, BS MacIntyre, I Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways. J. Endocrinol. 1990 126 473–481.
  • Zaidi, M Datta, HK Bevis, PJR Wimalawansa, SJ MacIntyre, I Amylin amide: A new bone-conserving peptide from the pancreas. Exp. Physiol. 1990 75 529–536.
  • Alam, ASMT Moonga, BS Bevis, PJR Huang, CLH Zaidi, M Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide (Val8Phe37). Biochem. Biophys. Commun. 1991 179 134–139.
  • Fleisch, H Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991 42 919–944.
  • Fleisch, H Russell, RGG Fransis, MD Diphosphonate inhibits the hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969 165 1262–1264.
  • Russell, RGG Bisaz, S Donath, A Fleisch, H Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosatasia, osteogenesis imperfecta and other disorders of bone. J. Clin. Invest. 1971 961–969.
  • Shinoda, H Adamek, G Felix, R Fleisch, H Schenk, R Hagan, P Structure activity relationships of various bisphosphonates. Calcif. Tissue. Int. 1983 35 87–99.
  • Bijvoet, OLM Hosking, DJ Lemkes, HHPJ Reitsma, PH Frulink, WB Development in the treatment of Paget's disease Endocrinology of calcium metabolism. Copp, Excerpta Medica Amsterdam/Oxford 1978 421 48–54.
  • Reitsma, PH Bijvoet, OLM Verlinden Ooms, H Van der Wee-Pals, LJA Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif. Tissue Int. 1980 32 145–147.
  • Schenk, R Eggli, P Felix, R Fleisch, H Rosini, S Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 1986 38 342–349.
  • Boonekamp, PM Lowik, CWGM Van der Wee-Pals, LJA Van Wijk-Van Lennep, MLL Bijvoet, OLM Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner. 1987 2 29–42.
  • Muhlbauer, RC Stutzer, A Schenk, R Janner, M Fleisch, H 1-Hydroxy-3-(methyl-pentylamino) propylidene-bisphosphonate (BM 21.0955), a potent new inhibitor of bone resorption. J. Bone Miner. Res. 1989 4 Suppl 1 S168.
  • Muhlbauer, RC Bauss, F Schenk, R Janner, M Bosies, E Strein, K Fleisch, H BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone. Miner. Res. 1991 6 1003–1011.
  • Bevan, JA Johnson, KY Slough, C Benedict, N Fleisch, H Skeletal effects of 2-(2-pyridinyl)-ethylidene-bisphosphonate in acute and subchronic rat studies. Calcif. Tissue Int. 1986 38 531.
  • Bevan, JA Franks, AF McOsker, JE Boyce, RW Buckingham, KW Bisphosphonate action in the oophorectomized rat: The effects of 2-(-pyridinyl)-1-hydroxyethlidenebis(phosphonate) on skeletal metabolism; comparison with etidronate. J. Bone Miner. Res. 1988 3 Suppl 1 S193.
  • Sietsema, WK Ebetino, FH Salvagno, AM Bevan, JA Antiresorptive dose-response relationship across three generations of bis-phosphonates. Drugs Exp. Clin. Res. 1989 15 389–396.
  • Fleisch, H Bisphosphonates: Mechanisms of action and clinical application Bone and mineral research. Annual 1 Peck, WA Amsterdam Oxford-Princeton, Excerpta Medica 1983 319–357.
  • Monkkonen, JA One year follow up study of the distribution of 14C-clodronate in mice and rats. Pharmacol. Toxicol. 1988 62 5153.
  • Powell, JH De Mark, BP Clinical pharmacokinetics of diphosphonates Bone resorption metastasis, and diphosphonates Garrafini, S Raven Press New York 1985 41–49.
  • Muhlbauer, RC Fleisch, H A method for continual monitoring of bone resorption in rats: Evidence for a diurnal rhythm. Am. J. Physiol. 1990 259 R679–R689.
  • Stutzer, A Fleisch, H Trechsel, U Shortand long-term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomised rats. Calcif. Tissue Int. 1988 43 294–299.
  • Thiebaud, D Jeager, P Burcckhardt, P A single-day treatment of tumor-induced hypercalcaemia by intravenous amino hydroxypropylidene bisphosphonate. J. Bone Miner. Res. 1986 1 555–562.
  • Fast, DK Felix, R Dowse, C Neuman, WF Fleisch, H The effects of bisphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem. J. 1978 172 97–107.
  • Felix, R Guenther, HL Fleisch, H The subcellular distribution of 14C dichloromethylene-bisphosphonate and 14C 1-hydroxy-eth-1,1-bisphosphonate in cultured calvaria cells. Calcif. Tissue Int. 1984 36 108–13.
  • Flanagan, AM Chambers, TJ Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner. 1989 6 33–43.
  • Felix, R Russell, RGG Fleisch, H The effect of several bisphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochimica et Biophysica Acta 1976 429 429–438.
  • Smirnova, IN Kudryavtseva, NA Komissarenko, SV Tarusova, NB Baykov, AA Bisphosphonates are potent inhibitors of mammalian inorganic pyrophosphatase. Arch. Biochem. Biophys. 1988 267 280–84.
  • Felix, R Bettex, JD Fleisch, H Effect of bisphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif. Tissue Int. 1981 33 549–552.
  • Carano, A Teitelbaum, SL Konsek, JD Schlesinger, PH Blair, HC Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990 85 456–461.
  • Valkema, R Visman, SF-JFE Papapoulos, SE Effects of long term low dose bisphosphonate (APD) on calcium balance and bone mineral content in patients with osteoporosis. Bone Min. 1989 5 183–192.
  • Reitsma, PH Bijvoet, OL Potokar, M van der Wee-Pals, LJ van Wijk-van Lennep, MM Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Calcif. Tissue Int. 1983 35 357–361.
  • Cecchini, MG Felix, R Fleisch, H Cooper, PH Effects of bisphosphonates on proliferation and viability of mouse bone marrow derived macrophages. J. Bone Miner. Res. 1987 2 135–142.
  • Cecchini, MG Fleisch, H Bisphosphonates in vitro specifically inhibit, among the hemopoietic series, the development of the mouse mononuclear phagocyte linege. J. Bone Miner. Res. 1990 5 1019–1027.
  • Martin, TJ Actions of calcitonin and mithramycin. Arthritis and Rheum. 1980 23 1131–1138.
  • Ryan, WC Schwartz, TB Perlia, CP Effects of mithramycin on Paget's disease of bone. Ann. Intern. Med. 1969 70 549–557.
  • Cortes, EP Holland, JF Moskowitz, R Depoli, E Effects of mithramycin on bone resorption in vitro. Cancer Res. 1972 32 7476.
  • Warrell, RP Murphy, WK Schulman, P O'Dwyer, PJ Heller, G A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer related hypercalcaemia. J. Clin. Oncol. 1991 9 1467–1475.
  • Tobias, J Chambers, TJ Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. Endocrinology 1989 125 1290–1295.
  • Chenu, C Pfeilschifter, J Mundy, GR Roodman, GD Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA 1988 85 5683–5687.
  • Bentz, H Nathan, RM Rosen, DM Armstrong, RM Thompson, AY Segarini, PR Matthews, MC Dasch, JR Piez, KA Seyedin, SM Purification and characterization of a unique osteoinductive factor from bovine bone. J. Biol. Chem. 1989 5 20805–20810.
  • Takahashi, N Mundy, GR Roodman, GD Recombinant human interferon-γ inhibits formation of human osteoclast-like cells. J. Immunol. 1986 137 3544–3549.
  • Perussia, B Dayton, ET Fanning, V Thiagarjan, P Hoxie, J Trinchieri, G Immune interferon and leucocyte conditioned medium induced normal and leukaemic myeloid cells to differentiate along the monocytic pathway. J. Exp. Med. 1983 158 2058–2080.
  • Weinberg, JB Hobbs, MM Misukonis, MA Recombinant human gamma interferon induces human monocyte polykaryon formation. Proc. Natl. Acad. Sci. USA 1984 81 4554–4557.
  • Alam, ASMT Moonga, BS Huang, CLH Zaidi, M Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp. Physiology 1992 In press.
  • Datta, HK Zaidi, M Wimalawansa, SJ Ghatei, MA Beacham, JL Bloom, SR MacIntyre, I In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem. Biophys. Res. Commun. 1989 162 876–881.
  • Zaidi, M Chambers, TJ Moonga, BS Oldoni, T Pasarella, E Soncini, R MacIntyre, I A new approach for calcitonin determination based on target cell responsiveness. J. Endocrinol. Invest. 1990 13 119–126.
  • Gelbey, SG Ghatei, MA Bretherton-Watt, D Zaidi, M Jones, PM Perera, T Beacham, J Girgis, S Bloom, SR Islet amyloid polypeptide (IAPP): Production by osteoblasts cell line and possible role as a paracrine regulator of osteoclast function in man. Clinical Science 1991 81 803–808.
  • Hui, SL Epstein, S Johnston, CC Jr A prospective study of bone mass in patients with Type I diabetes. J. Clin. Endocrinol. Metab. 1985 60 74–80.
  • Zaidi, M Alam, ASMT Shankar, VS Bax, BE Bax, CMR Moonga, BS Bevis, PJR Stevens, C Blake, DR Huang, CL-H Cellular biology of bone resorption. Biol. Rev. 1992 In press.
  • Garrett, IR Boyce, BF Oreffo, RO Bonewald, L Poser, J Mundy, GR Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J. Clin. Invest. 1990 85 632–639.
  • Key, LL Jr Reis, WL Taylor, RG Hays, BD Pitzer, BR Oxygen derived free radicals in osteoclasts: The specificity and location of the nitroblue tetrazolium reaction. Bone 1990 11 115–119.
  • Oursler, MJ Collin-Osdoby, P Li, L Schmitt, E Osdoby, P Evidence for an immunological and functional relationship between superoxide dismutase and a high molecular weight osteoclast plasma membrane glycoprotein. J. Cell Biochem. 1991 46 331–344.
  • Zaidi, M Datta, HK Patchell, A Moonga, BS MacIntyre, I ‘Calcium-activated’ intracellular calcium elevation: A novel mechanism of osteoclast regulation. Biochem. Biophys. Res. Commun. 1989 163 1461–1465.
  • Malgaroli, A Meldolesi, J Zambonin-Zallonea Teti, A Control of cytosolic free calcium in rat and chicken osteoclasts. J. Biol. Chem. 1989 264 14342–14347.
  • Zaidi, M Calcium ‘receptors’ on eukaryotic cells with special reference to the osteoclast Biosci. Rep. 1990 10 493–507.
  • Datta, HK MacIntyre, I Zaidi, M The effect of ionised calcium on the morphology and function of isolated rat osteoclasts. Biosci. Rep. 1989 9 247–251.
  • Miyauchi, A Hruska, KA Greenfield, EM Duncan, R Alvarez, J Barattolo, R Colucci, S Zambonin-Zallone, A Teitelbaum, SL Teti, A Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels extracellular calcium, controls podosome assembly and bone resorption. J. Cell Biol. 1990 111 2543–2552.
  • Zaidi, M Kerby, J Huang, CL-H Alam, ASMT Rathod, H Chambers, TJ Moonga, BS Divalent cations mimic the inhibitory effect of extracellular ionised calcium on bone resorption by isolated rat osteoclasts: Further evidence for a ‘calcium receptor’. J. Cell Physiol. 1991 149 422–427.
  • Zaidi, M Shankar, VS Bax, CMR Bax, BE Alam, ASMT Banerji, B Bevis, PJR Gill, JS Moonga, BS Huang, CL-H Characterisation of the osteoclast calcium receptor Calcium regulation and bone metabolism. Cohn, DV, Tashjian, AR Jr Elsevier Amsterdam 1992 In press.
  • Shankar, VS Bax, CMR Alam, ASMT Bax, BE Huang, CL-H Zaidi, M The osteoclast Ca2+ receptor is highly sensitive to activation by transition metal cations. Biochem. Biophys. Res. Commun. 1992 In press.
  • Shankar, VS Alam, ASMT Bax, CMR Bax, BE Pazianas, M Huang, CL-H Zaidi, M Activation and inactivation of the osteoclast Ca2+ receptor by the trivalent cation, La3+. Biochem. Biophys. Res. Commun. 1992 In press.
  • Bax, BE Alam, ASMT Banerji, B Bax, CMR Bevis, PJR Stevens, CR Moonga, BS Blake, DR Zaidi, M Stimulation of osteoclastic bone resorption by hydrogen peroxide (H2O2). Biochem. Biophys. Res. Commun. 1992 183 1153–1158.
  • MacIntyre, I Zaidi, M Alam, ASMT Datta, HK Moonga, BS Lidbury, PS Hecker, M Vane Jr Osteoclastic inhibition: An action of nitric oxide not mediated by cyclic GMP. Proc. Natl. Acad. Sci. USA 1991 88 2936–2940.
  • Alam, ASMT Gallagher, A Shankar, VS Ghatei, MA Datta, HK Huang, CLH Moonga, BS Chambers, TJ Bloom, SR Zaidi, M Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility implications for the vascular control of bone resorption. Endocrinology 1992 130 3617–3624.
  • Roodman, GD Osteoclast differentiation. Crit. Rev. Oral Biol. Med. 1991 2 389–409.
  • McSheehy, PMJ Chambers, TJ Osteoblastlike cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. Endocrinology 1986 119 1654–1659.
  • McSheehy, PMJ Chambers, TJ 1, 25-dihydroxyvitamin D3 stimulates rat osteoblastic bone resorption. J. Clin. Invest. 1987 80 425–429.
  • Davies, J Warwick, J Tutty, N Phillip, R Helfrich, M Horton, M The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J. Cell Biol. 1989 109 1817–1826.
  • Horton, MA Davies, J Perspectives: Adhesion receptors in bone. J. Bone Miner. Res. 1989 4 803–808.
  • Simpson, A Horton, MA Expression of the vitronectin receptor during embryonic development: An immunohistological study of the ontogeny of the osteoclast in the rabbit. Br. J. Exp. Pathol. 1989 70 257–265.
  • Webber, D Osdoby, P Hauchka, P Krukowski Correlation of an osteoclast antigen and ruled border on giant cells formed in response to resorbable substrates. J. Bone Miner. Res. 1990 5 401–410.
  • Baron, R Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec. 1989 224 317–324.
  • Parvinen, EK Slot, JW Vaarianen, HK Osteoclast acidifying enzymes, carbonic anhydrase II and H+-K+-ATPase immunogold localisation on ultracryosections. Calcif. Tissue Int. 1987 41 Suppl 2 20.
  • Tuukkanen, J Vaananen, HK Omeprazole, a specific inhibitor of H+-K+-ATPase inhibits bone resorption in vitro. Calcif. Tissue Intern. 1986 38 123–125.
  • Zaidi, M Modularity of osteoclast behaviour and mode-specific inhibition of osteoclast function. Biosci. Rep. 1990 10 547–556.
  • Silver, IA Murrills, RJ Etherington, DJ Microelectrode studies on acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res. 1988 175 266–276.
  • Donahue, HJ Ijima, K Goligorsky, MS Rubin, CT Rifkin, BR Regulation of cytoplasmic calcium concentration in tetracycline treated osteoclast. J. Bone Min. Res. in press.
  • Juhlin, CR Lundgren, S Johansson, H Lorentzen, Z Rask, L Larsson, E Rastad, J Akerstrom, G Klareskog, L 500-kilodalton calcium sensor regulating cytoplasmic Ca2+ in cytotrophoblast cells of human placenta. J. Biol. Chem. 1990 265 8275–8279.
  • Moonga, BS Datta, HK Bevis, PJR Huang, CL-H MacIntyre, I Zaidi, M Correlates of osteoclast function in the presence of perchlorate ions in the rat. Exp. Physiol. 1991 76 923–933.
  • Zaidi, M MacIntyre, I Datta, HK Intracellular calcium in the control of osteoclast function. II. Paradoxical elevation of cytosolic free calcium by verapamil. Biochem. Biophys. Res. Commun. 1990 167 807–812.
  • Bax, CMR Shankar, VS Huang, CL-H Zaidi, M Is the osteoclast calcium ‘receptor’ a receptor-operated calcium channel. Biochem. Biophys. Res. Commun. 1992 183 619–625.
  • Yang, G Condy, TE Boaro, M Wilkaen, HE Jones, P Nazhat, NB Saadalla-Nazhat, RA Blake, DR Free radical yield from the homolysis of peroxynitrous acid. Free Rad. Biol. Med. 1992 12 327–330.
  • Collin-Osdoby, P Oursler, MJ Webber, D Osdoby, P Osteoclast-specific monoclonal antibodies coupled to magnetic beads provide a rapid and efficient method of purifying avian osteoclasts. J. Bone Min. Res. 1991 6 11353–11365.
  • Selley, ML Bourne, DJ Bartlett, MR Tymms, KE Brook, AS Duffield, AM Ardlie, NG Occurence of (E)-4-hydroxy-2-nonenal in plasma and synovial fluid of patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 1992 51 481–484.
  • Parthasarathy, S Steinbrecher, UP Barnett, J Witzum, JL Steinberg, D Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA 1985 82 3000–3004.
  • Overgaard, K Hansen, MA Jensen, SB Christiansen, C Effect of salcalcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study. Br. Med. J. 1992 305 556–561.
  • Rico, H Hernandez, ER Revilla, M Gomez-Castnesana, F Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner. 1992 16 131–138.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.